BioMimics-3D® Vascular Stent System

The BioMimics-3D Vascular Stent System has a unique 3D helical geometry which imparts a gentle helical shape to the stented artery.

MIMICS-3D 3-year results published

The 3-year results for the MIMICS-3D “real-world” European registry have been published. The manuscript conclusions are that “the MIMICS 3D registry showed satisfying outcomes in patients treated with the helical centreline BioMimics 3D nitinol stent, which are comparable to those of drug-eluting stents. There was no difference in terms of CD-TLR, whether the stent was used alone or in combination with a DCB. This means that suboptimal results after DCB treatment should not be accepted as the combination of DCB plus BioMimics 3D results in good outcomes, and that DCB, in addition to BioMimics 3D stent treatment, may be an alternative to DES therapy when drug treatment is deemed necessary.”

Veryan & Otsuka

Veryan was founded in 2005 as the result of a technology spin out from Imperial College, London.

The Latest from Veryan

News, updates and press releases

BioMimics 3D® Vascular Stent System granted Good Design Award 2022

TOKYO, JAPAN – 07 OCTOBER 2022 – Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”, subsidiary of Otsuka Holdings Co., Ltd.) is pleased to announce that the BioMimics 3D Vascular Stent System has been granted a Good Design Award 2022 from the Japan Institute of Design Promotion.

Board Announcement – Appointment of new CEO

HORSHAM, UK – 01 SEPTEMBER 2022 – The Board of Veryan Holdings Ltd announces that, following 11 years of service, including 8 years as COO and 3 years as CEO, Nick Yeo has decided to leave Veryan to pursue new professional and personal goals.

MIMICS-3D EU 3-year results

Veryan Medical has confirmed the release at ISET 22 of the MIMICS-3D EU 3-year results by the study PI Michael Lichtenberg MD. MIMICS-3D EU is a prospective, multicentre, observational registry to evaluate the BioMimics 3D Vascular Stent System. The study evaluated safety, effectiveness and device performance within a real-world clinical population of 507 patients enrolled in 23 pan-European sites.

Get in touch

Find contact details and send us a message.